What are the latest updates from clinical trials of isatuximab for NDMM?

The Multiple Myeloma Hub was pleased to speak with Meral Beksaç, Istinye University Ankara Liv Hospital , Ankara, TR. We asked about the latest updates from clinical trials of isatuximab for newly diagnosed multiple myeloma.

In this interview, Meral Beksaç discussed the latest data from clinical trials evaluating isatuximab-based regimens in both transplant-eligible and transplant-ineligible patients. Beksaç reviewed key studies, including IMROZ, BENEFIT, GMMG-HD7, and REST, highlighting the efficacy of quadruplet regimens, such as isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) and isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in improving progression-free survival (PFS) and rates of measurable residual disease (MRD) negativity.

Key takeaways

• There is an increased use of quadruplet regimens such as Isa-VRd and Isa-KRd for the treatment of both transplant-eligible and transplant-ineligible patients. These combinations are showing promising results, particularly in PFS and MRD negativity rates.
• Tailoring regimens for patients, particularly those with features of high-risk disease, is vital. Quadruplet regimens including Isa-KRd are likely to be more effective, achieving better MRD negativity rates than other standard approaches.
• It is also important to personalize treatment approaches based on age and tolerability, particularly in patients who are frail.
• There are a lack of data for isatuximab-based maintenance therapies; however, ongoing research is evaluating the benefit of incorporating isatuximab into maintenance regimens in the future, such as the RAMP up/HEME-18 study (NCT05344833).
• There is potential for the use of carfilzomib-based regimens alongside isatuximab for high-risk patients in the future, based on promising data from the ISKIA, MIDAS, and GMMG-CONCEPT trial.
• MRD negativity remains a key goal of therapy in multiple myeloma, correlating with deeper remissions and improved long-term outcomes.
• Overall, while the emerging data from clinical trials are promising, further research is required to refine regimens and determine the most effective strategies for both transplant-eligible and transplant-ineligible patients.

This educational resource is independently supported by Sanofi All content was developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.